氢氧化铝与硫糖铝作为尿毒症磷结合剂的比较
Aluminium hydroxide versus sucralfate as a phosphate binder in uraemia.
作者信息
Leung A C, Henderson I S, Halls D J, Dobbie J W
出版信息
Br Med J (Clin Res Ed). 1983 Apr 30;286(6375):1379-81. doi: 10.1136/bmj.286.6375.1379.
Abstract
In an attempt to discover a phosphate binding agent for use in uraemia that would not lead to appreciable systemic absorption of aluminium the effect of sucralfate was evaluated after three weeks and compared with that of the existing standard agent aluminium hydroxide. Sucralfate caused a decrease in serum phosphate concentration comparable with that obtained with aluminium hydroxide, but similar absorption of aluminium resulted. Sucralfate may be the phosphate binder of choice in patients with uraemia and peptic ulceration; care should be taken in using large doses of the drug in patients with normal renal function.
摘要
为了找到一种用于尿毒症的不会导致铝大量全身吸收的磷酸盐结合剂，在三周后评估了硫糖铝的效果，并与现有的标准制剂氢氧化铝进行了比较。硫糖铝使血清磷酸盐浓度降低的程度与氢氧化铝相当，但铝的吸收情况相似。硫糖铝可能是尿毒症合并消化性溃疡患者的首选磷酸盐结合剂；肾功能正常的患者使用大剂量该药物时应谨慎。
相似文献
1
Aluminium hydroxide versus sucralfate as a phosphate binder in uraemia.氢氧化铝与硫糖铝作为尿毒症磷结合剂的比较
Br Med J (Clin Res Ed). 1983 Apr 30;286(6375):1379-81. doi: 10.1136/bmj.286.6375.1379.
2
Phosphate-binding effects of sucralfate in patients with chronic renal failure.硫糖铝对慢性肾衰竭患者的磷结合作用。
Am J Kidney Dis. 1989 Mar;13(3):194-9. doi: 10.1016/s0272-6386(89)80052-6.
3
Aluminum hydroxide, calcium carbonate and calcium acetate in chronic intermittent hemodialysis patients.慢性间歇性血液透析患者中的氢氧化铝、碳酸钙和醋酸钙
Clin Nephrol. 1996 Feb;45(2):111-9.
4
Aluminium sucrose biscuit fillings to control hyperphosphataemia in patients undergoing dialysis.铝蔗糖饼干馅料用于控制透析患者的高磷血症。
Br Med J (Clin Res Ed). 1981 Jul 25;283(6286):268. doi: 10.1136/bmj.283.6286.268.
5
6
Calcium carbonate as a phosphate binder in dialysis patients: evaluation of an enteric-coated preparation and effect of additional aluminium hydroxide on hyperaluminaemia.
Klin Wochenschr. 1991 Jan 22;69(2):59-67. doi: 10.1007/BF01666818.
7
[Iatrogenic aluminum osteopathy in a uremic infant].[一名尿毒症婴儿的医源性铝骨病]
Monatsschr Kinderheilkd. 1986 May;134(5):279-81.
8
1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis.1α(OH)D3 一α-羟基胆钙化醇——一种活性维生素 D 类似物。关于慢性透析的尿毒症患者继发性甲状旁腺功能亢进症预防和治疗的临床研究。
Dan Med Bull. 2008 Nov;55(4):186-210.
9
[Calcium carbonate for the treatment of hyperphosphatemia in chronic hemodialysis patients].碳酸钙用于治疗慢性血液透析患者的高磷血症
Schweiz Med Wochenschr. 1990 Mar 3;120(9):295-8.
10
[Aluminum hydroxide treatment of hyperphosphatemia in uremia].[氢氧化铝治疗尿毒症高磷血症]
Lakartidningen. 1972 May 3;69(19):2319-20.
引用本文的文献
1
Serum aluminum in 176 feline patients with application to the diagnostic approach to a tremoring patient with kidney disease receiving aluminum hydroxide therapy.176例猫患者的血清铝含量及其在诊断接受氢氧化铝治疗的肾病震颤患者中的应用。
BMC Vet Res. 2025 May 8;21(1):327. doi: 10.1186/s12917-025-04788-8.
2
Drug-Dosing Adjustment in Dogs and Cats with Chronic Kidney Disease.患有慢性肾病的犬猫的药物剂量调整
Animals (Basel). 2022 Jan 21;12(3):262. doi: 10.3390/ani12030262.
3
ACVIM consensus statement: Support for rational administration of gastrointestinal protectants to dogs and cats.美国兽医内科学会共识声明：支持合理给犬猫使用胃肠道保护剂。
J Vet Intern Med. 2018 Nov;32(6):1823-1840. doi: 10.1111/jvim.15337. Epub 2018 Oct 31.
4
Science review: The use of proton pump inhibitors for gastric acid suppression in critical illness.科学综述：质子泵抑制剂在危重症中用于抑制胃酸分泌的应用
Crit Care. 2005 Feb;9(1):45-50. doi: 10.1186/cc2980. Epub 2004 Oct 8.
5
Pharmacokinetic optimisation of the treatment of peptic ulcer in patients with renal failure.肾衰竭患者消化性溃疡治疗的药代动力学优化
Clin Pharmacokinet. 1994 Nov;27(5):393-408. doi: 10.2165/00003088-199427050-00006.
6
Sucralfate. A review of its pharmacodynamic properties and therapeutic use in peptic ulcer disease.硫糖铝。其药效学特性及在消化性溃疡疾病中的治疗应用综述。
Drugs. 1984 Mar;27(3):194-209. doi: 10.2165/00003495-198427030-00002.
7
Assessing the safety of drugs for the long-term treatment of peptic ulcers.评估用于消化性溃疡长期治疗的药物安全性。
Gut. 1984 Dec;25(12):1416-23. doi: 10.1136/gut.25.12.1416.
8
Antacid and sucralfate-induced hypophosphatemic osteomalacia: a case report and review of the literature.抗酸剂和硫糖铝所致低磷性骨软化症：一例报告及文献复习
Calcif Tissue Int. 1990 Nov;47(5):291-5. doi: 10.1007/BF02555911.
9
Clinical pharmacokinetics of drugs used in the treatment of gastrointestinal diseases (Part II).用于治疗胃肠道疾病的药物的临床药代动力学（第二部分）。
Clin Pharmacokinet. 1990 Aug;19(2):94-125. doi: 10.2165/00003088-199019020-00002.
10
Renal effects of peptic ulcer therapy.消化性溃疡治疗的肾脏效应。
Drug Saf. 1992 Jul-Aug;7(4):282-91. doi: 10.2165/00002018-199207040-00004.
本文引用的文献
1
Serum aluminum and continuous ambulatory peritoneal dialysis.血清铝与持续性非卧床腹膜透析
Ann Intern Med. 1980 Jan;92(1):130-1. doi: 10.7326/0003-4819-92-1-130_2.
2
3
Sucralfate: a review of drug tolerance and safety.
J Clin Gastroenterol. 1981;3(Suppl 2):181-4.
4
Efficacy of sucralfate for duodenal ulcers: a multicenter, double-blind trial.硫糖铝治疗十二指肠溃疡的疗效：一项多中心双盲试验。
J Clin Gastroenterol. 1981;3(Suppl 2):153-7.
5
Plasma Aluminum levels of patients on long term sucralfate therapy.长期使用硫糖铝治疗患者的血浆铝水平。
Res Commun Chem Pathol Pharmacol. 1982 Mar;35(3):515-8.
6
Acute aluminium intoxication in patients on continuous ambulatory peritoneal dialysis.持续性非卧床腹膜透析患者的急性铝中毒
Lancet. 1982 Jan 9;1(8263):103-4. doi: 10.1016/s0140-6736(82)90237-9.
7
Hyperaluminaemia from aluminum resins in renal failure.肾衰竭患者因铝树脂导致的高铝血症。
Lancet. 1970 Sep 5;2(7671):494-6. doi: 10.1016/s0140-6736(70)90113-3.
8
The dialysis encephalopathy syndrome. Possible aluminum intoxication.透析性脑病综合征。可能的铝中毒。
N Engl J Med. 1976 Jan 22;294(4):184-8. doi: 10.1056/NEJM197601222940402.
9
Composition of the domestic water supply and the incidence of fractures and encephalopathy in patients on home dialysis.家庭透析患者的生活用水成分与骨折及脑病发病率
Br Med J. 1977 Sep 10;2(6088):657-60. doi: 10.1136/bmj.2.6088.657.
10
Gastrointestinal absorption of aluminum from aluminum-containing antacids.含铝抗酸剂中铝的胃肠道吸收。
N Engl J Med. 1977 Jun 16;296(24):1389-90. doi: 10.1056/NEJM197706162962407.
Zotero 插件